PURPOSE: We have shown previously that oral feeding of green tea polyphenols (GTP) to transgenic adenocarcinoma of the mouse prostate mice in a purely chemopreventive setting significantly inhibits prostate cancer development. To translate this to a human situation, the present study was designed to identify the stage of prostate cancer that is most vulnerable to chemopreventive intervention by GTP. EXPERIMENTAL DESIGN: GTP infusion (0.1% in drinking water) to transgenic adenocarcinoma of the mouse prostate was initiated at ages representing different stage of the disease: (a) 6 weeks (group 1, normal prostate), (b) 12 weeks (group 2, prostatic intraepithelial neoplasia), (c) 18 weeks (group 3, well-differentiated adenocarcinoma), and (b) 28 weeks (group 4, moderately differentiated adenocarcinoma). At age 32 weeks, subsets of animals were evaluated by magnetic resonance imaging, ultrasound, and prostate weight and for serum insulin-like growth factor (IGF)-I/IGF binding protein-3 and IGF signaling. RESULTS: Tumor-free survival was extended to 38 weeks (P < 0.001) in group 1, 31 weeks (P < 0.01) in group 2, and 24 weeks (P < 0.05) in group 3 compared with 19 weeks in water-fed controls. Median life expectancy was 68 weeks in group 1, 63 weeks in group 2, 56 weeks in group 3, and 51 weeks in group 4 compared with 42 weeks in the control mice. IGF-I and its downstream targets including phosphatidylinositol 3-kinase, pAkt, and phosphorylated extracellular signal-regulated kinase were significantly inhibited only when intervention was initiated early when prostatic intraepithelial neoplasia lesions were common. CONCLUSIONS: Our studies indicate that chemopreventive potential of GTP decreases with advancing stage of the disease and underscore the need to design appropriate chemoprevention clinical trails.
PURPOSE: We have shown previously that oral feeding of green teapolyphenols (GTP) to transgenicadenocarcinoma of the mouse prostate mice in a purely chemopreventive setting significantly inhibits prostate cancer development. To translate this to a human situation, the present study was designed to identify the stage of prostate cancer that is most vulnerable to chemopreventive intervention by GTP. EXPERIMENTAL DESIGN:GTP infusion (0.1% in drinking water) to transgenicadenocarcinoma of the mouse prostate was initiated at ages representing different stage of the disease: (a) 6 weeks (group 1, normal prostate), (b) 12 weeks (group 2, prostatic intraepithelial neoplasia), (c) 18 weeks (group 3, well-differentiated adenocarcinoma), and (b) 28 weeks (group 4, moderately differentiated adenocarcinoma). At age 32 weeks, subsets of animals were evaluated by magnetic resonance imaging, ultrasound, and prostate weight and for serum insulin-like growth factor (IGF)-I/IGF binding protein-3 and IGF signaling. RESULTS:Tumor-free survival was extended to 38 weeks (P < 0.001) in group 1, 31 weeks (P < 0.01) in group 2, and 24 weeks (P < 0.05) in group 3 compared with 19 weeks in water-fed controls. Median life expectancy was 68 weeks in group 1, 63 weeks in group 2, 56 weeks in group 3, and 51 weeks in group 4 compared with 42 weeks in the control mice. IGF-I and its downstream targets including phosphatidylinositol 3-kinase, pAkt, and phosphorylated extracellular signal-regulated kinase were significantly inhibited only when intervention was initiated early when prostatic intraepithelial neoplasia lesions were common. CONCLUSIONS: Our studies indicate that chemopreventive potential of GTP decreases with advancing stage of the disease and underscore the need to design appropriate chemoprevention clinical trails.
Authors: Aminah Jatoi; Neil Ellison; Patrick A Burch; Jeff A Sloan; Shaker R Dakhil; Paul Novotny; Winston Tan; Tom R Fitch; Kendrith M Rowland; Charles Y F Young; Patrick J Flynn Journal: Cancer Date: 2003-03-15 Impact factor: 6.860
Authors: P Finne; A Auvinen; H Koistinen; W M Zhang; L Määttänen; S Rannikko; T Tammela; M Seppälä; M Hakama; U H Stenman Journal: J Clin Endocrinol Metab Date: 2000-08 Impact factor: 5.958
Authors: Pradip K Majumder; Jen Jen Yeh; Daniel J George; Phillip G Febbo; Jennifer Kum; Qi Xue; Rachel Bikoff; Hongfeng Ma; Philip W Kantoff; Todd R Golub; Massimo Loda; William R Sellers Journal: Proc Natl Acad Sci U S A Date: 2003-06-10 Impact factor: 11.205
Authors: June M Chan; Meir J Stampfer; Jing Ma; Peter Gann; J Michael Gaziano; Michael Pollak; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2002-07-17 Impact factor: 13.506
Authors: Marian L Neuhouser; Jeannette Schenk; Yoon Ju Song; Catherine M Tangen; Phyllis J Goodman; Michael Pollak; David F Penson; Ian M Thompson; Alan R Kristal Journal: Prostate Date: 2008-09-15 Impact factor: 4.104
Authors: Susanne M Henning; Piwen Wang; Jonathan Said; Clara Magyar; Brandon Castor; Ngan Doan; Carmen Tosity; Aune Moro; Kun Gao; Luyi Li; David Heber Journal: J Nutr Biochem Date: 2012-03-08 Impact factor: 6.048
Authors: Mike M Nguyen; Frederick R Ahmann; Raymond B Nagle; Chiu-Hsieh Hsu; Joseph A Tangrea; Howard L Parnes; Mitchell H Sokoloff; Matthew B Gretzer; H-H Sherry Chow Journal: Cancer Prev Res (Phila) Date: 2011-11-01
Authors: Nagi B Kumar; Julio Pow-Sang; Kathleen M Egan; Philippe E Spiess; Shohreh Dickinson; Raoul Salup; Mohamed Helal; Jerry McLarty; Christopher R Williams; Fred Schreiber; Howard L Parnes; Said Sebti; Aslam Kazi; Loveleen Kang; Gwen Quinn; Tiffany Smith; Binglin Yue; Karen Diaz; Ganna Chornokur; Theresa Crocker; Michael J Schell Journal: Cancer Prev Res (Phila) Date: 2015-04-14
Authors: Shannon R Morey Kinney; Wa Zhang; Marien Pascual; John M Greally; Bryan M Gillard; Ellen Karasik; Barbara A Foster; Adam R Karpf Journal: Cancer Prev Res (Phila) Date: 2009-11-24